ZELgor 250mg Tablet contains Abiraterone Acetate, a potent androgen biosynthesis inhibitor used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone Acetate works by selectively inhibiting the enzyme CYP17A1, which is critical in the production of androgens not only in the testes but also in the adrenal glands and prostate tumor tissue. By reducing androgen levels, ZELgor effectively slows the progression of prostate cancer that is resistant to conventional hormone therapy. This medication is typically administered orally once daily on an empty stomach, often in combination with prednisone to mitigate mineralocorticoid-related side effects such as hypertension, hypokalemia, and fluid retention. Patients receiving ZELgor should be monitored regularly for liver function abnormalities, electrolyte imbalances, and blood pressure changes. Common adverse effects include fatigue, joint swelling, hot flashes, and gastrointestinal disturbances. ZELgor is contraindicated in patients with hypersensitivity to Abiraterone Acetate or any of its excipients and should be used cautiously in those with pre-existing liver impairment. It is essential to adhere to prescribed dosing and follow-up schedules to optimize therapeutic outcomes and minimize potential risks associated with treatment.